Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a…
By admin at 22 November, 2009, 4:00 pm
The objective of this study was to compare bleeding patterns of women using a contraceptive combination of 30 mcg ethinylestradiol (EE) and 3 mg drospirenone (DRSP) continuously or cyclically. Menstrual-related symptoms were also evaluated.Study Design: This open, prospective, randomized study evaluated 78 women using the EE/DRSP combination continuously for 168 days or for six 28-day cycles, each followed by a 7-day hormone-free interval. A diary with pre-established scales was used to assess the frequency and intensity of bleeding and menstrual-related symptoms.Results: Amenorrhea increased with continuous use; 62.2% of women with continuous use were amenorrheic at the end of treatment (95% CI: 46.6–77.8%).
Read more from the original source:
Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a…
Related posts:
- Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20μg plus drospirenone 3mg administered in a… Abstract: Objective: To investigate the effects of an ethinylestradiol (EE)...
- Combined contraceptive ring versus combined oral contraceptive (30-μg ethinylestradiol and 3-mg drospirenone) Conclusions: NuvaRing is a good alternative to a COC. It...
- Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in… Abstract: Background: A prospective randomized trial was conducted to compare...
- Self-medication with antibiotics for the treatment of menstrual symptoms in southwest Nigeria: a cross-sectional study Background: Self-medication with antibiotics is an important factor contributing to...
- Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate… Conclusions: The low-dose COC 0.02 mg EE/2 mg CMA administered...
No comments yet.